From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
- PMID: 11426642
- DOI: 10.1038/sj.onc.1204102
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
Abstract
The confluence of two distinct but related activities in the past 10 years has dramatically accelerated efforts towards the discovery and development of novel drugs to treat cancer. The first is a rapidly emerging understanding that a number of distinct tyrosine kinases play roles in diverse but fundamentally important aspects of tumor progression (growth, survival, metastasis and angiogenesis). The second is the discovery that small molecule compounds have the capacity to potently and selectively inhibit the biochemical function of tyrosine kinases by competing for ATP binding at the enzyme catalytic site. These observations have been conjoined in major efforts to bring forward into clinical development novel cancer drugs with the potential to provide both clinical efficacy and improved tolerability. The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical tumors (receptor and/or ligand-competitive antibodies, intrabodies, antisense ribonucleotides, ribozymes, phosphatase inhibitors or SH2/SH3-directed agents). Selected tyrosine kinase inhibitors, known or believed to be in development in cancer treatment trials, are summarized as are some of the key issues that must be addressed if these compounds are to be developed into clinically useful cancer chemotherapeutic agents.
Similar articles
-
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.Curr Opin Chem Biol. 2004 Aug;8(4):432-41. doi: 10.1016/j.cbpa.2004.06.009. Curr Opin Chem Biol. 2004. PMID: 15288254 Review.
-
Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.Curr Opin Drug Discov Devel. 2002 Mar;5(2):214-24. Curr Opin Drug Discov Devel. 2002. PMID: 11926128 Review.
-
Receptor tyrosine kinase inhibitors as anti-angiogenic agents.Curr Opin Investig Drugs. 2004 Jun;5(6):597-604. Curr Opin Investig Drugs. 2004. PMID: 15242247 Review.
-
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.Anticancer Drug Des. 2000 Feb;15(1):29-41. Anticancer Drug Des. 2000. PMID: 10888034 Review.
-
Targeting protein kinases in cancer therapy.Curr Opin Drug Discov Devel. 2002 Sep;5(5):701-12. Curr Opin Drug Discov Devel. 2002. PMID: 12630290 Review.
Cited by
-
YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.Arch Toxicol. 2024 May;98(5):1437-1455. doi: 10.1007/s00204-024-03693-7. Epub 2024 Mar 5. Arch Toxicol. 2024. PMID: 38443724
-
MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going.Cancers (Basel). 2022 Nov 22;14(23):5731. doi: 10.3390/cancers14235731. Cancers (Basel). 2022. PMID: 36497213 Free PMC article. Review.
-
Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies.Front Pharmacol. 2022 Nov 15;13:1027890. doi: 10.3389/fphar.2022.1027890. eCollection 2022. Front Pharmacol. 2022. PMID: 36457709 Free PMC article.
-
TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non-Small Cell Lung Cancer.Front Genet. 2022 May 13;13:881875. doi: 10.3389/fgene.2022.881875. eCollection 2022. Front Genet. 2022. PMID: 35646083 Free PMC article.
-
Absorption, metabolism, excretion, and safety of [14C]almonertinib in healthy Chinese subjects.Ann Transl Med. 2021 May;9(10):867. doi: 10.21037/atm-21-1606. Ann Transl Med. 2021. PMID: 34164501 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous